中信建投发布研报称，2025年，核心产品泰它西普新增适应症获批后快速放量，维迪西妥单抗联合治疗 方案数据优异，同时RC28的DME适应症上市申请获受理；在研管线中RC148获突破性疗法认定，临床 数据持续验证价值。整体看，公司商业化进程提速，管线梯队布局完善，看好公司后续发展。 本文源自：智通财经网 智通财经获悉，荣昌生物(09995)午后涨超7%，截至发稿，涨6.39%，报90.75港元，成交额3.19亿港 元。 消息面上，据公众号，2025年ESMO年会上，维迪西妥单抗联合特瑞普利单抗对比化疗一线治疗HER2 表达的局部晚期或转移性尿路上皮癌Ⅲ期临床研究发布。甬兴证券发布研报称，维迪西妥联合免疫疗效 优异，标志着尿路上皮癌治疗格局重大变革。 ...

消息面上，据公众号，2025年ESMO年会上，维迪西妥单抗联合特瑞普利单抗对比化疗一线治疗HER2 表达的局部晚期或转移性尿路上皮癌Ⅲ期临床研究发布。甬兴证券发布研报称，维迪西妥联合免疫疗效 优异，标志着尿路上皮癌治疗格局重大变革。 中信建投发布研报称，2025年，核心产品泰它西普新增适应症获批后快速放量，维迪西妥单抗联合治疗 方案数据优异，同时RC28的DME适应症上市申请获受理；在研管线中RC148获突破性疗法认定，临床 数据持续验证价值。整体看，公司商业化进程提速，管线梯队布局完善，看好公司后续发展。 智通财经APP获悉，荣昌生物(09995)午后涨超7%，截至发稿，涨6.39%，报90.75港元，成交额3.19亿港 元。 ...

中信建投（601066）发布研报称，2025年，核心产品泰它西普新增适应症获批后快速放量，维迪西妥单 抗联合治疗方案数据优异，同时RC28的DME适应症上市申请获受理；在研管线中RC148获突破性疗法 认定，临床数据持续验证价值。整体看，公司商业化进程提速，管线梯队布局完善，看好公司后续发 展。 荣昌生物(09995)午后涨超7%，截至发稿，涨6.39%，报90.75港元，成交额3.19亿港元。 消息面上，据公众号，2025年ESMO年会上，维迪西妥单抗联合特瑞普利单抗对比化疗一线治疗HER2 表达的局部晚期或转移性尿路上皮癌Ⅲ期临床研究发布。甬兴证券发布研报称，维迪西妥联合免疫疗效 优异，标志着尿路上皮癌治疗格局重大变革。 ...

Market Overview - The Hang Seng Index rose by 0.46%, gaining 119 points to reach 26,013 points, while the Hang Seng Tech Index increased by 0.51%. The morning trading volume in Hong Kong was HKD 114 billion [1] Company Performance - Meituan-W (03690) saw a morning increase of 5.85%, while Alibaba indicated a significant reduction in investment for Taobao Flash Sale expected in the next quarter [1] - Eastern Airlines (00670) experienced a rise of over 6%, benefiting from improved oil cost management [1] Biotechnology Sector - The Hang Seng Biotechnology Index increased by over 2%. Rongchang Biotech (09995) rose by over 5%, and Kangfang Biotech (09926) increased by over 4%. China Biopharmaceutical (01177) rose by 2.59% due to a significant breakthrough in HER2 dual-target ADC for breast cancer treatment [2] - Junshi Biosciences (01877) also saw an increase of over 3% as it plans to submit for listing following the successful Phase III clinical trial of Toripalimab subcutaneous injection [2] Other Notable Stocks - Basilea Pharmaceutica-B (02616) rose by over 6% after the European Commission approved a new indication for Sugliquin [3] - GDS Holdings (09698) increased by nearly 4% due to improved supply of domestic AI chips, with Morgan Stanley expecting a surge in orders in the second half of next year [3] - Longi Green Energy (06869) rose by nearly 7%, driven by interest in Google's TPU chips, with institutions optimistic about growth driven by AI data communication [3] - Smoore International (06969) increased by over 4% after signing a long-term procurement agreement for battery cells with EVE Energy to secure supply for its e-cigarette products [3] Alibaba Financial Results - Alibaba-W (09988) experienced a decline of over 2% during trading, with its adjusted net profit for the second fiscal quarter dropping by 72% year-on-year [4]

Market Overview - The Hang Seng Index increased by 0.46%, gaining 119 points to reach 26,013 points, while the Hang Seng Tech Index rose by 0.51%. The morning trading volume in Hong Kong was HKD 114 billion [1]. Airline Sector - Airline stocks led the gains, with China Eastern Airlines (00670) rising over 6% due to improved oil cost dynamics benefiting airline performance [2]. Biotechnology Sector - The Hang Seng Biotechnology Index rose over 2%. Rongchang Biopharmaceutical (09995) increased by over 5%, and Kangfang Biotech (09926) rose over 4%. China Biopharmaceutical (01177) gained 2.59% following significant breakthroughs in its self-developed HER2 dual-target ADC for breast cancer. Junshi Biosciences (01877) also saw an increase of over 3% as its Toripalimab subcutaneous injection Phase III clinical trial met its primary endpoint, with plans for subsequent listing application [3]. Pharmaceutical Sector - Basilea Pharmaceutica (02616) rose over 6% after the European Commission approved a new indication for Sugliquide [4]. AI and Technology Sector - GDS Holdings (09698) increased nearly 4% as domestic AI chip supply improved, with Morgan Stanley projecting a surge in orders by the second half of next year [5]. - Changfei Optical Fiber (06869) rose nearly 7% due to increased interest in Google's TPU chips, with institutions optimistic about AI-driven growth. Smoore International (06969) gained over 4% after signing a long-term battery cell procurement agreement with EVE Energy to secure supply for its electronic cigarette products [6]. E-commerce Sector - Alibaba Group (09988) saw a decline of over 2% during trading, with its adjusted net profit for the second fiscal quarter dropping 72% year-on-year [7].

Group 1 - The Hang Seng Index rose by 0.46%, gaining 119 points to close at 26,013 points, while the Hang Seng Tech Index increased by 0.51%. The morning trading volume in Hong Kong reached HKD 114 billion [1] - Meituan-W (03690) saw a morning increase of 5.85%, while Alibaba indicated a significant reduction in investment for Taobao Flash Sale expected in the next quarter [1] - Airline stocks performed well, with China Eastern Airlines (00670) rising over 6% due to improved oil cost benefits for airline performance [1] Group 2 - The Hang Seng Biotechnology Index increased by over 2%, with Rongchang Biologics (09995) rising over 5% and Kangfang Biologics (09926) up over 4% [2] - China Biopharmaceutical (01177) rose by 2.59% after its subsidiary achieved a significant breakthrough in HER2 dual-target ADC for breast cancer [2] - Junshi Biosciences (01877) increased by over 3% as its Toripalimab subcutaneous injection Phase III clinical trial met its primary endpoint, with plans for subsequent listing application [2] - Basilea Pharmaceutica-B (02616) rose over 6% after the European Commission approved a new indication for Sugliumab [2] - GDS Holdings Limited-SW (09698) increased by nearly 4% as domestic AI chip supply improves, with Morgan Stanley expecting a surge in orders in the second half of next year [2] Group 3 - Changfei Optical Fiber (601869) and Optical Cable (06869) rose nearly 7%, driven by interest in Google's TPU chips, with institutions optimistic about AI-driven growth in data communication [3] - Smoore International (06969) increased by over 4% after signing a long-term procurement agreement for battery cells with EVE Energy (300014) to secure supply for electronic cigarette products [3] - Alibaba-W (09988) fell over 2% as its adjusted net profit for the second fiscal quarter decreased by 72% year-on-year [3]

来源：新浪证券-红岸工作室 11月18日，君实生物跌1.76%，成交额2.74亿元，换手率0.95%，总市值383.98亿元。 异动分析 创新药+生物疫苗+猴痘概念 1、2024年年报，公司具备完整的从创新药物的发现和开发、 在全球范围内的临床研究、 大规模生产到 商业化的全产业链能力， 旨在成为立足中国、 布局全球的创新医药公司。 公司坚持质量为本、 求真务 实、 诚信合规、 追求卓越的企业价值观， 致力于通过源头创新以及合作开发等形式来研发 first-in-class （同类首创）或 best-in-class（同类最优） 的药物。 通过卓越的创新药物发现能力、 强大的生物技术研 发能力和大规模生产能力， 公司已成功开发出极具市场潜力的药品组合， 多项产品具有里程碑意义： 核心产品之一特瑞普利单抗是国内首个获得 NMPA 批准上市的国产抗 PD-1 单克隆抗体， 截至本报告 披露日已在中国内地获批 11 项适应症， 另有一项 sNDA 已受理， 其中多项为公司独家或领先适应 症， 特瑞普利单抗还是 FDA 批准上市的首个中国自主研发和生产的创新生物药， 截至本报告披露日， 特瑞普利单抗已在中国内地、 中 ...

Core Viewpoint - Junshi Biosciences is positioned as a comprehensive innovative pharmaceutical company with capabilities spanning drug discovery, clinical research, large-scale production, and commercialization, aiming for a global footprint while being rooted in China [2] Group 1: Company Overview - Junshi Biosciences has developed a strong portfolio of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received 11 indications in mainland China and is also approved in multiple countries including the US and EU [2] - The company is actively engaged in the development of early-stage products, with several expected to enter critical registration clinical trials by 2025 [2] - The company’s revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [7] Group 2: Recent Developments - Junshi Biosciences is collaborating with various research institutions and universities to develop vaccines, including those for monkeypox and Zika, which are currently in preclinical development [3] - A partnership has been established with Peking University and other institutions to jointly develop a recombinant protein vaccine for monkeypox [3] Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, reflecting a year-on-year growth of 42.06%, while the net profit attributable to the parent company was -596 million yuan, a 35.72% increase year-on-year [8] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% [8] Group 4: Market Activity - On November 13, Junshi Biosciences' stock rose by 2.38%, with a trading volume of 341 million yuan and a turnover rate of 1.14%, bringing the total market capitalization to 40.246 billion yuan [1] - The stock has seen a net inflow of 34.14 million yuan from major investors, indicating a slight increase in institutional interest [4][5]

Major Events - Bluestar Jiahe Services (02606.HK) plans to repurchase up to 10% of its issued H-shares [1] - China People's Insurance Group (01339.HK) reported original premium income of 97.985 billion yuan in January, a year-on-year increase of 6.67% [1] - Hengteng Network (00136.HK) signed a strategic cooperation agreement with Evergrande Tourism Group [1] Financial Data - New Star Printing (01975.HK) achieved a net profit of 27.5 million HKD in the interim period, with an interim dividend of 1.5 HKD cents [1] Earnings Forecast - Qihua Environmental Protection (00976.HK) expects an increase in annual net loss [1] - Zhuyou Intelligent Manufacturing Technology (00726.HK) anticipates a net profit increase of approximately 40.8% for the year [1] - Birmingham Sports (02309.HK) raised its earnings forecast, expecting a mid-term profit of 70 million HKD [1] - Huazhang Technology (01673.HK) expects a mid-term profit of 15 to 20 million yuan, turning from loss to profit year-on-year [1] - Raffles Interior (01376.HK) anticipates a net loss of 4.5 million Singapore dollars for the 2020 fiscal year [1] - Fengcheng Holdings (08216.HK) expects a net profit increase of over 50% for the year [1] - New Fengtai Group (01771.HK) forecasts a net profit growth of approximately 20% for the year [1] - Yefeng Group (01695.HK) expects an annual loss not exceeding 4 million Malaysian ringgit [1] Operational Data - China People's Insurance Group (01339.HK) reported original premium income of 97.985 billion yuan in January, a year-on-year increase of 6.67% [1] - New China Life Insurance (01336.HK) reported original premium income of 34.63 billion yuan in January, a year-on-year increase of 12.78% [1] - China Property & Casualty Insurance (02328.HK) reported original insurance premium income of 53.112 billion yuan in January, a year-on-year increase of 1.2% [1] - China Metallurgical Group (01618.HK) signed new contracts worth 103.59 billion yuan in January, a year-on-year increase of 129.7% [1] - China Eastern Airlines (00670.HK) reported a 60.59% year-on-year decline in passenger turnover in January [1] - Sinopec Oilfield Services (01033.HK) recently signed overseas contracts worth 2.323 billion yuan [1] - China Southern Airlines (01055.HK) reported a 59.16% year-on-year decline in passenger turnover in January [1] - Huili Group (00806.HK) reported total managed assets of approximately 14.8 billion USD at the end of January [1]

Core Viewpoint - The company, Junshi Biosciences, aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation in drug development [2][3]. Company Overview - Junshi Biosciences was founded on December 27, 2012, and went public on July 15, 2020. Its main business involves the research and commercialization of monoclonal antibody drugs and other therapeutic proteins, with 90.67% of revenue coming from drug sales [7]. - As of September 30, 2025, the company reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [8]. Product Development - The company has developed a strong portfolio of innovative drugs, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi Biosciences is also advancing its pipeline with Tifcemalimab, the first anti-BTLA monoclonal antibody entering clinical development, currently undergoing two Phase III trials [2]. Collaborations and Research - The company is collaborating with institutions such as Peking University and the Chinese Academy of Sciences to develop vaccines, including a monkeypox vaccine, which is currently in the preclinical development stage [3][8]. Market Performance - On November 7, the company's stock fell by 1.92%, with a trading volume of 292 million yuan and a market capitalization of 38.799 billion yuan [1]. - The stock has seen a net outflow of 458.376 million yuan from major investors, indicating a trend of reduced holdings over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 41.33 yuan, with the current price approaching a resistance level of 38.99 yuan, suggesting potential volatility in the near term [6].